259 related articles for article (PubMed ID: 19902390)
21. Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.
Garcia-Cremades M; Melillo N; Troconiz IF; Magni P
Clin Transl Sci; 2020 May; 13(3):608-617. PubMed ID: 32043298
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine: we've reached the end of the beginning.
Green MR
Semin Oncol; 1996 Oct; 23(5 Suppl 10):99-100. PubMed ID: 8893890
[No Abstract] [Full Text] [Related]
23. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
[TBL] [Abstract][Full Text] [Related]
24. Introduction. Gemcitabine: ten years of clinical experience.
Cartei G; Labianca R
Ann Oncol; 2006 May; 17 Suppl 5():v5-6. PubMed ID: 18309538
[No Abstract] [Full Text] [Related]
25. Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.
Harris M; Bhuvaneshwar K; Natarajan T; Sheahan L; Wang D; Tadesse MG; Shoulson I; Filice R; Steadman K; Pishvaian MJ; Madhavan S; Deeken J
Pharmacogenet Genomics; 2014 Feb; 24(2):81-93. PubMed ID: 24401833
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
Ueno H; Kiyosawa K; Kaniwa N
Br J Cancer; 2007 Jul; 97(2):145-51. PubMed ID: 17595663
[TBL] [Abstract][Full Text] [Related]
27. Review of gemcitabine-based combinations for platinum-resistant ovarian cancer.
Sehouli J
Int J Gynecol Cancer; 2005; 15 Suppl 1():23-30. PubMed ID: 15839955
[TBL] [Abstract][Full Text] [Related]
28. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
[TBL] [Abstract][Full Text] [Related]
29. [Gemcitabine: Applications and perspectives].
Tumori; 1997; 83(5):877-80. PubMed ID: 9446252
[No Abstract] [Full Text] [Related]
30. Clinical, toxicological and pharmacological aspects of gemcitabine.
Guchelaar HJ; Richel DJ; van Knapen A
Cancer Treat Rev; 1996 Jan; 22(1):15-31. PubMed ID: 8625330
[No Abstract] [Full Text] [Related]
31. Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
Poplin EA; Corbett T; Flaherty L; Tarasoff P; Redman BG; Valdivieso M; Baker L
Invest New Drugs; 1992 Aug; 10(3):165-70. PubMed ID: 1428726
[TBL] [Abstract][Full Text] [Related]
32. [The role of membrane transporters in cellular resistance of pancreatic carcinoma to gemcitabine].
Mohelníková-Duchonová B; Soucek P
Klin Onkol; 2010; 23(5):306-10. PubMed ID: 21061681
[TBL] [Abstract][Full Text] [Related]
33. The emerging role of gemcitabine in conditioning regimens for hematopoietic stem cell transplantation.
Wang E; Gulbis A; Hart JW; Nieto Y
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1382-9. PubMed ID: 24816580
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine: novel combination of efficacy and tolerability.
Anticancer Drugs; 1993 Dec; 4(6):671. PubMed ID: 8298167
[No Abstract] [Full Text] [Related]
35. Gemcitabine and UFT plus oral calcium folinate: phase I study.
Philip PA; Ibrahim D; Zalupski M; Arlauskas P; Shields A
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):116-9. PubMed ID: 10442378
[TBL] [Abstract][Full Text] [Related]
36. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine: ten years of clinical experience. Proceedings of a workshop. September 19-21, 2005. Monastier di Treviso, Italy.
Ann Oncol; 2006 May; 17 Suppl 5():v5-200. PubMed ID: 18309567
[No Abstract] [Full Text] [Related]
38. The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study.
Weick JK; Crowley JJ; Hussein MA; Moore DF; Barlogie B;
Invest New Drugs; 2002 Feb; 20(1):117-21. PubMed ID: 12003187
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetics in pancreatic cancer.
Tourkantonis IS; Peponi E; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):335-9. PubMed ID: 25076337
[TBL] [Abstract][Full Text] [Related]
40. Tumor resistance to antimetabolites.
Kinsella AR; Smith D
Gen Pharmacol; 1998 May; 30(5):623-6. PubMed ID: 9559310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
